ClinicalTrials.gg
TerminatedNCT03399578Updated Oct 20, 2021

Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)

A Phase 1 interventional study of ChAdOx1 MERS in MERS (Middle East Respiratory Syndrome), sponsored by University of Oxford. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-20.

Sponsored by University of Oxford · Phase 1, Interventional, and Prevention

Why this study was terminated
The scientific questions proposed remain relevant, but will now be addressed in a larger phase II immunogenicity trial of the ChAdOx1 MERS vaccine given at 2 doses.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Coronavirus Infections by University of Oxford — 1 open to participants now, 1 under way, none of them phase 3. Coronavirus Infections · University of Oxford.

Enrollment
10th of 10
29 · median 688
Started
2018
the only one that year
Phase 1
3 of 11
none open now
Registered
1st of 11
by date

Among the 11 studies in Coronavirus Infections by University of Oxford, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 3 in phase 1, and was the 1st registered.

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.

Browse Coronavirus Infections studies →

Open to participants now

1 of the 11 studies in Coronavirus Infections by University of Oxford is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Coronavirus Infections by University of Oxford, or all of them as a file.
02

Study summary

This is a clinical trial in which healthy volunteers will be administered an experimental MERS vaccine. The vaccine ChAdOx1 MERS will be administered alone both as a single administration and with a homologous prime-booster.

Read the detailed description

All vaccinations will be administered intramuscularly. In Groups 1-3, each volunteer will receive one vaccination in total. In Groups 4 and 5, each volunteer will receive two vaccinations in total.

There are five different vaccine schedules:

Group 1 (n=6) will receive 5 x 10\^9 vp ChAdOx1 MERS .

Group 2 (n=9) will receive 2.5 x 10\^10 vp ChAdOx1 MERS.

Group 3 (n=9) will receive 5 x 10\^10 vp ChAdOx1 MERS.

Group 4 (n=6-12) will receive 2.5 x 10\^10 vp ChAdOx1 MERS at week 0 followed by a boost of 2.5 x 10\^10 vp ChAdOx1 MERS at week 26.

Group 5 (n=6-12) will receive 2.5 x 10\^10 vp ChAdOx1 MERS at week 0 followed by a boost of 2.5 x 10\^10 vp ChAdOx1 MERS at week 4.

The study will assess the safety of the vaccines, and the immune responses to the vaccinations. Immune responses are measured by tests on blood samples.

Healthy adult volunteers will be recruited in Oxford, England.

03

Conditions studied

  • MERS (Middle East Respiratory Syndrome)
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The volunteer must satisfy all the following criteria to be eligible for the study:

  1. Healthy adults aged 18 to 50 years
  2. Able and willing (in the Investigator's opinion) to comply with all study requirements
  3. Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner or access this medical history electronically.
  4. For females only, willingness to practice continuous effective during the study and a negative pregnancy test on the day(s) of screening and vaccination
  5. Agreement to refrain from blood donation during the course of the study
  6. Provide written

Exclusion criteria

Exclusion Criteria:

The volunteer may not enter the study if any of the following apply:

  1. Participation in another research study involving receipt of an product in the 30 days preceding enrolment, or planned use during the study period
  2. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccine).
  3. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  4. Any confirmed or suspected or immunodeficient state, including infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical are allowed)
  5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
  6. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
  7. Any history of anaphylaxis in relation to vaccination
  8. Pregnancy, lactation or willingness/intention to become pregnant during the study
  9. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
  10. History of serious psychiatric condition likely to affect participation in the study
  11. Bleeding disorder (eg. factor deficiency, coagulopathy or disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture
  12. Any other serious chronic illness requiring hospital specialist supervision
  13. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
  14. Suspected or known injecting drug abuse in the 5 years preceding enrolment
  15. Seropositive for surface antigen (HBsAg)
  16. Seropositive for virus (antibodies to HCV)
  17. Any abnormal finding on screening biochemistry or haematology blood tests or urinalysis
  18. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
  19. Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate
  20. Prior exposure to MERS-CoV (serology will be requested at the discretion of the investigator)
  21. History of allergic reaction to Aminoglycoside antibiotics
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Group 1

    Group 1 volunteers (n= 6) will be administered ChAdOx1 MERS, 5 x 10\^9 vp through intramuscular route.

    Biological: ChAdOx1 MERS

  • Experimental
    Group 2

    Group 2 volunteers (n= 9) will be administered ChAdOx1 MERS, 2.5 x 10\^10 vp through intramuscular route.

    Biological: ChAdOx1 MERS

  • Experimental
    Group 3

    Group 3 volunteers (n= 9) will be administered ChAdOx1 MERS, 5 x 10\^10 vp through intramuscular route.

    Biological: ChAdOx1 MERS

  • Experimental
    Group 4

    Group 4 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10\^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10\^10 vp at week 26. Both administrations will be given through intramuscular route.

    Biological: ChAdOx1 MERS

  • Experimental
    Group 5

    Group 5 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10\^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10\^10 vp at week 4. Both administrations will be given through intramuscular route.

    Biological: ChAdOx1 MERS

Interventions

  • BiologicalChAdOx1 MERS

    The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

06

What researchers measure

Primary outcomes

  1. Occurrence of solicited and unsolicited local and systemic adverse events

    The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events. Change from baseline for safety laboratory measures will also be collected. Occurrence of serious adverse events will be collected during the whole study duration

    Time frame: up to 28 days following vaccination

Secondary outcomes

  1. Measures of immunogenicity to the ChAdOx1 MERS vaccine

    ELISA to quantify antibodies to MERS Spike protein antigen Ex vivo ELISpot responses to MERS Spike protein antigen

    Time frame: 12 months

07

Study locations

1 site
  • Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital
    Oxford, United Kingdom
08

References and documents

Publications

  • Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, Mair C, Makinson R, Sheridan J, Rohde C, Halwe S, Jeong Y, Park YS, Kim JO, Song M, Boyd A, Tran N, Silman D, Poulton I, Datoo M, Marshall J, Themistocleous Y, Lawrie A, Roberts R, Berrie E, Becker S, Lambe T, Hill A, Ewer K, Gilbert S. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020 Jul;20(7):816-826. doi: 10.1016/S1473-3099(20)30160-2. Epub 2020 Apr 21. Erratum In: Lancet Infect Dis. 2020 Jul;20(7):e148. doi: 10.1016/S1473-3099(20)30393-5. Lancet Infect Dis. 2020 Jul;20(7):e148. doi: 10.1016/S1473-3099(20)30508-9. PubMed 32325038 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Sep 2021, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2018
First posted
Jan 16, 2018
StartActual
Mar 14, 2018
Primary completionActual
Sep 17, 2021
CompletionActual
Sep 17, 2021
Last update
Oct 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03399578
Responsible party
Sponsor
First posted
Jan 16, 2018
Start date
Mar 14, 2018
Primary completion
Sep 17, 2021
Completion
Sep 17, 2021
Last update
Oct 20, 2021

Study contacts

Adrian V Hill, DPhil FRCP
principal investigator · Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion